Introduction
============

COPA syndrome has been classified under the category of autoinflammatory disorders in the 2017 Update of the Classification of Inborn Errors of Immunity by International Union of Immunological Societies (IUIS).[@b1-tacg-12-011] In recent years, many important immune dysregulation syndromes such as autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) caused by mutated *AIRE*; immune dysregulation, polyendocrinopathy, and enteropathy caused by mutations in *FOXP3* (IPEX); and autoimmune lymphoproliferative syndrome (ALPS) caused by mutated Fas/FasL have unveiled the role of autoimmune regulator protein, T-regulatory cells, and Fas/FasL, respectively, in immune tolerance. Having studied the role of these molecules, we now have a significantly clearer view of the underlying pathophysiology of some of the monogenic autoimmune diseases.

Autoimmune manifestations with an onset at a very early age or of familial nature are likely due to monogenic defects. Normally, non-immune tissues are mostly affected in pedi-atric autoimmune diseases such as skin, kidneys, joints, and endocrine organs (type 1 diabetes). Autoimmunity involving the lungs is rare in pediatric population. Granulomatosis with polyangiitis and microscopic polyangiiitis collectively called ANCA-associated vasculitis are the established cause of autoimmune pulmonary hemorrhage. Anti-myeloperoxidase and anti-proteinase 3 antibodies are found to be elevated in ANCA-associated vasculitides.[@b2-tacg-12-011] Children having ANCA-associated vasculitis frequently present with fever, renal disease, and malaise along with pulmonary hemorrhage.[@b3-tacg-12-011]--[@b5-tacg-12-011]

Diseases such as systemic lupus erythematosus (SLE) and other immune dysregulation diseases such as juvenile dermatomyositis and scleroderma may progress into nonspecific interstitial pneumonia (NSIP).[@b6-tacg-12-011]--[@b9-tacg-12-011] Recent findings of gain of function mutations in *TMEM173* causing STING-associated vasculopathy of infancy (SAVI) syndrome provide clues about interstitial lung disease (ILD) and its association with an increased production of IFNs.[@b10-tacg-12-011],[@b11-tacg-12-011] Patients with COPA syndrome share some of the clinical features with SAVI syndrome, such as ILD and an upregulated IFN signature.[@b10-tacg-12-011]--[@b13-tacg-12-011]

Large number of patients with STAT1 GOF mutations has chronic mucocutaneous candidiasis (CMC) and recurrent lower respiratory tract bacterial infections. Patients with germline STAT3 GOF mutations have been associated with early-onset multiorgan autoimmunity, lymphoproliferation, early-onset growth failure, and may have severe recurrent infections. Studies have also shown an association of STAT3 GOF with interstitial pneumonitis and role of STAT3 signaling in interstitial and fibrotic lung disease pathogenesis.[@b14-tacg-12-011]

The etiopathogenesis of COPA syndrome is unknown, but it is hypothesized that disturbances in protein trafficking pathway can lead to endoplasmic reticulum (ER) stress that results in unfolded protein response (UPR) activation, thereby resulting in upregulation of T helper (Th)-17 cells and hence autoimmunity.[@b15-tacg-12-011] However, due to ubiquitous expression of *COPA* gene, it might have different effects on different types of cells and tissues. It might represent a mixed pattern disorder like type 1 interferonopathies having features of both autoimmunity and autoinflammation.[@b16-tacg-12-011]

Considering the fact that aforementioned diseases with confirmed mutations have overlapping clinical symptoms with the COPA syndrome, here in this review, we have explained the clinical and genetic features of the poorly understood disease.

What is COPA syndrome?
----------------------

COPA syndrome is a monogenic autoimmune disease described in 2015 that usually affects the lungs and joints. Most of the patients with COPA syndrome present with DPLD or diffuse alveolar hemorrhage (DAH) and arthritis.[@b15-tacg-12-011]--[@b17-tacg-12-011]

COPA syndrome is called so because it is caused by missense mutations in the *COPA* gene located on chromosome 1 (1q23.2), which is inherited in an autosomal dominant mode in a heterozygous fashion. COPI is a heptameric protein associated with membranes by ARF1, a GTP-binding protein. This subunit binds to proteins having dilysine residues at carboxyl-terminal end and is involved in retrograde protein trafficking.[@b12-tacg-12-011] Excessive ER stress in COPA syndrome is probably related to disrupted retrograde transport causing aberrant cellular autophagy leading to an impaired early endosomal function.

Earlier, these processes were not thought of causing immune dysregulation, hence, studying COPA syndrome would be highly helpful in understanding links between immune dysregulation and intracellular trafficking of vesicular proteins. Furthermore, it would also pave way for new therapeutic targets for the management of patients with COPA syndrome. COPα is expressed on all the cells of the body, but clinical phenotypes are seen only on pulmonary, joint, and renal tissues, which are supposedly more vulnerable to this mutation.

Clinical and laboratory features of COPA syndrome
-------------------------------------------------

COPA syndrome is associated with immune dysregulation. Clinical manifestations usually start at early childhood, with an average age of presentation at 3.5 years. Seven studies reported 32 individuals having confirmed mutations in the *COPA* gene.[@b18-tacg-12-011] There is no racial predilection for COPA syndrome. It has been reported in Caucasians, Asians, African Americans, and Icelandic-Nordic population. Gender bias has been reported in the expressivity and penetrance of the disease with 13 of the 14 females with *COPA* mutations showing clinical signs of the disease.[@b18-tacg-12-011] Pulmonary manifestations are present in the majority of the patients, either as ILD or DAH. The lung histopathology in these patients has revealed features similar to that of ILD in other systemic autoimmune diseases. Arthritis as the predominant clinical manifestation is seen in 95% of COPA patients ([Table 1](#t1-tacg-12-011){ref-type="table"}). Renal manifestations such as immune complex glomerulonephritis have been documented in four of the 21 patients in a cohort by Watkin et al.[@b15-tacg-12-011]

Laboratory tests have revealed elevated levels of various inflammatory markers such as rheumatoid fac tor, erythrocyte sedimentation rate (ESR), and CRP. Forty-three percent of cases reported autoantibodies to rheumatoid factor.[@b15-tacg-12-011] Positive ANA titer and rheumatoid factor have been reported in most of the patients, while other antibodies such as perinuclear ANCA (pANCA), anti-myeloperoxidase antibodies, cytoplasmic ANCA (cANCA), and anti-proteinase three antibodies may also be present in few patients. Upregulation of Th17 priming cytokines (IL-17A, IL-23, IL-6, and IL-1β) with various other pro-inflammatory cytokines including IL-1β and IL-6 while downregulating IFN-γ-secreting Th1 cells has also been observed.[@b12-tacg-12-011] Watkin et al[@b15-tacg-12-011] demonstrated a significant change in the phenotype of Th cells toward the Th17 phenotype, which is an effector population of T-cells involved in the process of autoimmunity.[@b19-tacg-12-011],[@b20-tacg-12-011] Despite an increased Th17 cells, psoriasis or inflammatory bowel disease (IBD) has not been reported in COPA patients till date.

Molecular genetics
------------------

All *COPA* mutations identified till date are missense mutations in exons that encode WD40 domain of the COPA protein. Size of the *COPA* gene is 54 kb (54,978 bp), with mRNA sequence of 5,666 bp. Size of genomic DNA is 37 kb, while its coding sequence is of 3,702 bp. It has 33 exons ranging from 67 to 611 bp in size with 32 introns present in the gene ranging from 80 bp to 4 kb ([Figure 1](#f1-tacg-12-011){ref-type="fig"}). The untranscribed and non-coding portions of the 5′ of the gene are rich in GC content consistent with its being a housekeeping gene.[@b21-tacg-12-011]

Studies have reported *COPA* gene to be highly constrained, which had low scores in both missense and loss of function mutations.[@b22-tacg-12-011],[@b23-tacg-12-011] The predicted deleterious effects due to the loss-of-function mutations in *COPA* gene and missense mutations in the WD40 domain appears to be same.[@b27-tacg-12-011] Watkin et al have reported four different heterozygous missense mutations affecting WD5 and WD6 repeats in WD40 domain of *COPA* gene. These mutations were identified in 30 individuals from five different families who were affected with autoimmune interstitial lung, joint, and kidney disease.[@b15-tacg-12-011] WES and targeted sequencing were done for the identification of unique mutations in these families. Hot spot mutations reported include Arg233His, Asp243Gly, Glu241Lys, and Lys230Asn.[@b15-tacg-12-011] Prediction algorithms (SIFT and Polyphen-2 scores) predicted all the mutations to be damaging and disease causing. Most common mutation reported is (p.Arg233His) followed by (p.Glu241 Lys).

Tsui et al[@b17-tacg-12-011] reported that all of these missense mutations occur in the eighth and ninth exon of the *COPA* gene that encodes C' of the WD40 domain in COPα protein. Impaired binding to proteins targeted for retrograde transport has been shown in two mutant variants in in vitro studies. All identified variants were found to be deleterious by various prediction tools and were located in 14 amino acid sequence in the highly conserved WD40 region of *COPA* ([Figure 1](#f1-tacg-12-011){ref-type="fig"}). WD repeats are highly conserved units involved in cell division, determination of cell fate, and vesicular trafficking.[@b24-tacg-12-011]--[@b26-tacg-12-011] Another WES study in six family members (three affected and three unaffected) revealed recurrent missense mutations with heterozygous pattern (p.Glu241Lys) in WD40 domain of *COPA* gene in an Icelandic family.[@b27-tacg-12-011] Another study revealed (p.W240R) variant in the *COPA* gene in a 12-year-old boy who was presented with dyspnea, clubbing, and fatigue.[@b28-tacg-12-011] Volpi et al reported c.698G\>A mutation by targeted next-generation sequencing. Mutation was confirmed by Sanger sequencing in the patient and her mother.[@b13-tacg-12-011]

Quantitative PCR and immunoblots were carried out for determining the expression level of the COPA transcript and its protein patterns.[@b15-tacg-12-011] Results revealed no significant differences between COPA expression in patients and controls.[@b15-tacg-12-011] Normal distribution of COPA protein was demonstrated by imaging analysis throughout the cell, indicating that the variant did not cause mislocalization of COPA to impair its function.[@b15-tacg-12-011],[@b29-tacg-12-011]

ER stress and UPR
-----------------

Synthesis of protein and its folding takes place in ER. Cells have molecular chaperones (BiP-binding immunoglobulin protein) for folding of the polypeptide chain into a specific conformation so as to avoid inappropriate interactions.[@b30-tacg-12-011] Properly folded proteins are destined to secretory pathway through Golgi apparatus, while misfolded proteins are degraded by ER-associated degradation (ERAD). Physiological states that demand more protein folding or cause disruption of protein folding by various stimuli or states in which the number of proteins entering the ER exceeds its folding capacity causes imbalance and hence resulting in improperly folded proteins to gather in the ER -- a phenomenon termed as ER stress. Eukaryotic cells have various intracellular signaling paths that respond to improperly folded proteins and defend against stress in ER to ensure the fidelity of protein folding. These processes are called UPR that causes alterations at RNA and protein level to cope with ER stress and sort out protein folding defects.[@b31-tacg-12-011],[@b32-tacg-12-011]

BiP (molecular chaperone) is responsible for appropriate folding of polypeptide chains in ER and provides shielding from inappropriate interactions.[@b34-tacg-12-011] During stress, ER stress sensors get activated through sequestration of BiP to improperly folded polypeptide chains.[@b35-tacg-12-011] However, in non-stressed cells, BiP binds to IRE1α, PERK, and ATF6 stress sensors resulting in their inactivation. Three UPR signaling pathways are activated by the three ER stress sensors: PERK, IRE1α, and ATF6.[@b31-tacg-12-011],[@b32-tacg-12-011] These transmembrane proteins sense unfolded proteins through their ER-luminal domain and target them to the ER membrane. IRE1α,/XBP-1 arm of UPR pathway is responsible for induction of IL-6 during differentiation of plasma cells while the function is taken over by PERK/ATF4 pathway during glucose insufficiency in cancer cells.[@b33-tacg-12-011] Activated IRE1α selectively causes splicing of intron of 26 bp from XBP1 mRNA and causes its nuclear translocation and hence upregulating the expression of target genes related to UPR signaling pathway.[@b31-tacg-12-011],[@b32-tacg-12-011] During ER stress, BiP removal activates PERK causing the units to dimerize and resulting in trans-autophosphorylation. Kinase activity of PERK causes phosphorylation of eIF2α and reduces the translation initiation. However, phosphorylated eIF2α specifically translates ATF4 mRNA and increases the expression of UPR-related genes.[@b36-tacg-12-011],[@b37-tacg-12-011] ATF6 after release from BiP gets cleaved by (S1P and S2P proteases) in Golgi apparatus, giving an active ATF6 p50 that upregulates UPR-related gene expression. Cleaved ATF6 induces the transcription of genes that promote proper protein folding, their maturation, and finally their secretion.[@b38-tacg-12-011],[@b39-tacg-12-011] However, if UPR fails to solve protein folding problems, it will initiate apoptosis mediated by CHOP, thereby protecting the organism. In addition to anterograde transport, some proteins require ER export chaperones or receptors for their exit into transport vesicles.

ER stress and inflammation
--------------------------

Recent studies evidenced that molecular relation exists between ER stress and inflammation. Reactive oxygen species production, calcium release from ER, NF-κB activation, and proteins like p38 and c-Jun-N-terminal kinase cause initiation of inflammatory pathways.[@b38-tacg-12-011] NF-κB has an important role in regulation of transcription and is an important mediator of inflammation.[@b39-tacg-12-011] Activation of NF-κB is responsible for inflammatory gene expression, which is caused by ER stress by driving the production of various adhesion molecules, pro-inflammatory cytokines and chemokines.^42^ NF-κB signaling gets activated by UPR through PERK--eIF2α-mediated weakening of translation response to ER stress ([Figure 2](#f2-tacg-12-011){ref-type="fig"}). This increases in NF-κB to IκB ratio, thereby causing its nuclear localization.[@b40-tacg-12-011] In the absence of an activation signal, NF-κB binds to IκB and exists in an inactive dimeric form. However, activation signal causes phosphorylation of IκB, thereby causing its proteasomal degradation and hence translocates NF-κB to nucleus. NF-κB signaling pathway gets activated by all three arms of UPR.[@b41-tacg-12-011] Also, IRE1 interacts with TRAF2 and IκB kinase, which increases the expression of inflammatory genes by activating NF-κB.^42^ Studies have shown that PERK disruption can nullify ER stress-induced STAT3 activation and hence their subsequent gene expression.

Functional tests have also been performed for the assessment of enhanced ER stress in COPA patients. Protein expression and mRNA level (qPCR) of COPA in thapsigargin-treated B lymphoblastoid cell line (BLCL) was determined. Results revealed significantly elevated levels of BiP in COPA patients compared to control.[@b15-tacg-12-011] In addition, siRNA knockdown experiments in human embryonic kidney (HEK) cells were performed for analyzing the involvement and the potential role of mutant COPA in ER stress. Results indicate increased ER stress due to decreased COPA expression marked by increased BiP expression-ER stress marker.[@b15-tacg-12-011] When mutant and wild type COPA were overexpressed in the human embryonic kidney cells (HEK), increased expression of BiP was seen in COPA mutants as compared to wild type.[@b15-tacg-12-011] Impaired binding of yeast Wbp1 to the mutant COPA (E241K) was demonstrated in a study.[@b15-tacg-12-011] When E241K mutant COPA cell line was transfected with a reporter protein having dilysine retrieval signal, impaired binding of E241K variant COPA was demonstrated by immunoprecipitation assay. This provides evidence for improper binding of variant COPA and dilysine tagged proteins, showing defective protein trafficking.[@b43-tacg-12-011]

ROS, ER stress, and UPR activation
----------------------------------

ER stress is related to accumulation of intracellular ROS that leads to oxidative stress. Intramolecular and intermolecular disulphide bond formation requires oxidizing environment leading to generation of ROS.[@b44-tacg-12-011] Excessive protein folding in ER can cause ROS accumulation, thereby eliciting an inflammatory response.[@b38-tacg-12-011] Excessive ROS then targets calcium channels present on ER, resulting in upregulation of calcium release from ER into the cytosol, which then gets concentrated in the mitochondrial matrix disrupting the electron transport chain (ETC), thereby further increasing ROS production.[@b38-tacg-12-011] This ROS will further aggravate calcium release from ER and can disrupt protein folding process causing ER stress, UPR induction, and further enhances ROS production.[@b38-tacg-12-011]

ER stress in lung diseases and arthritis
----------------------------------------

The lungs and gut share embryological origins, but most of the studies done so far had concentrated on the gut. Animal studies demonstrated inflammation of colon in IRE1β knockout mouse.[@b45-tacg-12-011] Studies have been done on ER stress in alveolar epithelium, but the involvement of particular cells that involves ER stress in lungs is still not clear. Studies revealed the involvement of *COPA* gene mutations in arthritis and ILD with UPR activation observed in the epithelium of lungs.[@b15-tacg-12-011] Studies on CHOP (bZip transcription factor) expression revealed its significant high levels in the presence of mutant COPA or when COPA expression was reduced.[@b46-tacg-12-011] Microarray analysis in patients with myositis has revealed the increased expression of glucose-regulated protein of 78 kDa (GRP78), suggesting the involvement of the ER response in the skeletal muscle damage in autoimmune myositis.[@b47-tacg-12-011]

Renal manifestations
--------------------

Studies demonstrated an increased risk for renal disease in patients with COPA syndrome with age of onset from mid to late teenage. Glomerular disease (44%) with or without immune complex deposition, proteinuria, and decreased kidney function have been documented in patients with COPA.[@b12-tacg-12-011] Renal histology showed glomerulopathy. Another study reported acquired renal disease in a subset of patients (21%).[@b17-tacg-12-011] Different types of glomerular lesions were present in patients with COPA syndrome. IgA nephropathy with necrotizing lesions has been reported in some patients, while others had mesangial hypercellularity. Necrotizing lesions were present in 75% of patients with renal disease. Recent study documented clear cell renal carcinoma, renal cysts, nephrolithiasis, and pyelonephritis as important clinical manifestations of disease.[@b48-tacg-12-011] A study reported a patient with chronic renal disease who undergo kidney transplantation. Early recognition of COPA might be able to reduce risk of glomerular injury.[@b12-tacg-12-011] Immune-mediated kidney disease in combination with DAH has also been documented in three patients.[@b17-tacg-12-011] However, normal kidney function has been reported in a study of two families carrying the p.Glu241Lys mutation, suggesting its non-deleterious effects on renal function.[@b15-tacg-12-011]

ER stress in central nervous system (CNS)
-----------------------------------------

Accumulation of improper proteins in ER of neuroglia and neurons is the pathological hallmark of large number of neurodegenerative disorders that results in the clinical manifestations of various CNS diseases. ER stress is reported in Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The UPR pathway induced in response to ER stress brings about changes at transcriptional and protein level to minimize stress and to reduce protein misfolding. However, prolonged ER stress causes disruption of the protective role of UPR, resulting in activation of inflammatory pathway and other apoptotic signals, hence contributing to neuronal dysfunction. ER stress in astrocytes of murine activates PERK-mediated inflammatory pathway in vitro, suggesting that the role of astrocytes in neurotoxic inflammation during ER dysfunction.[@b49-tacg-12-011]--[@b51-tacg-12-011] However, ER stress resulting in CNS phenotype has not been reported in any of the COPA patients thus far.

ER stress in gut and skin
-------------------------

The epithelial cells of gut are exposed to complex microbiota, antigens, and various bacterial toxins. During bacterial infection, the excessive production of MUC2 or defensins exerts a significant burden on ER in intestinal epithelial cells that poses threat to protein folding capacity and hence causes ER stress. Recent studies reported the association of ER stress and UPR with susceptibility to IBD, Crohn's disease, and ulcerative colitis.[@b52-tacg-12-011],[@b53-tacg-12-011] Genetic defects in UPR-related genes are also associated with IBD due to unfolded proteins in ER and overt immune response in epithelial cells.[@b54-tacg-12-011] An increased ER stress also results in epidermal differentiation so that it might be involved in psoriasis.[@b55-tacg-12-011],[@b56-tacg-12-011] Studies reported the role of ER stress in damage of melanocytes in vitiligo patients and results in cell degeneration.[@b57-tacg-12-011] However, the contribution of ER stress response in disease pathology remains to be elucidated.

Conclusion
==========

Improper protein folding in ER is associated with the pathogenesis of a large number of disorders. In addition, stress in ER can result in lung diseases by triggering inflammatory signaling and by modulating differentiation status. Discovery of a molecular relationship between a defective COPI protein transport pathway and autoimmunity establishes a new aim for understanding the involvement of intracellular transport in autoimmunity and as a potential therapeutic option in a large number of diseases. Future studies are needed to explain that how mutant COPA is associated with ER stress and induction of autoinflammatory diseases. This new approach will help in the development of new therapeutic strategies for combating stress in cells and inflammation.
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###### 

Clinical phenotype and pattern of *COPA* gene mutations in different cohorts

  Serial number   Study                               Year   Country                                 No. of patients        Demographic features   Mutation   Clinical features                                
  --------------- ----------------------------------- ------ --------------------------------------- ---------------------- ---------------------- ---------- ------------------------------------------------ -------------------------------------------------------------------------------------------------
  1\.             Watkin et al[@b15-tacg-12-011]      2015   USA                                     21 (from 5 families)   3.5                    8:13       Arg233His, Asp243Gly, Glu241Lys, and Lys230Asn   Joint pain; arthritis; hemorrhage; presence of ANA, ANCA, and Rh factor
  2\.             Jensson et al[@b27-tacg-12-011]     2017   Iceland                                 3                      4                      1:2        p.Glu241Lys                                      Follicular bronchitis, respiratory infection, diffuse capacity defect, lung obstruction
  3\.             Volpi et al[@b16-tacg-12-011]       2017   Italy                                   1                      3                      1 F        c.698G\>A                                        Polyarticular arthritis, chronic cough, ↑Rh factor, interstitial lung disease
  4\.             Tsui et al[@b17-tacg-12-011]        2018   Multiple centers (USA, Italy, Canada)   14                     5                      3:11       Arg233His, Asp243Gly, Glu241Lys, and Lys230Asn   Joint pain, hemoptysis diffuse parenchymal lung disease, arthritis, diffuse alveolar hemorrhage
  5\.             Noorelahi et al[@b28-tacg-12-011]   2018   USA                                     1                      12                     1 M        p.W240R                                          Dyspnea on exertion, fatigue and clubbing, and interstitial pneumonia

**Abbreviations:** ANA, anti-nuclear antibody; ANCA, anti-neutrophil cytoplasmic antibody; F, female; M, male.
